Related Experiment Video
Updated: Jun 4, 2025
13:28
Methodology for Sputum Induction and Laboratory Processing
Published on: December 17, 2017
27.4K
Genotype-Guided Asthma Treatment Reduces Exacerbations in Children: Meta-Analysis of Two Randomized Control Trials.
Elise M A Slob1,2,3, Susanne J H Vijverberg1, Tom Ruffles4,5
1Department of Pulmonary Medicine, AmsterdamUMC, University of Amsterdam, Amsterdam, The Netherlands.
Allergy
|December 26, 2024
Summary
Genotype-guided treatment for children with asthma may reduce exacerbations. This approach personalizes care by considering the ADRB2 Arg16Gly polymorphism (rs1042713) for step-up therapy decisions.
Area of Science:
- Pharmacogenomics
- Pediatric Pulmonology
- Asthma Management
Background:
- Inhaled corticosteroids (ICS) and long-acting beta2-agonists (LABA) are standard asthma treatments.
- Some children show poor response to LABA add-on therapy, potentially due to the ADRB2 Arg16Gly polymorphism (rs1042713).
- The A allele (Arg16) is linked to increased exacerbations despite LABA use.
Purpose of the Study:
- To investigate if genotype-guided treatment improves asthma outcomes in children.
- To evaluate the impact of ADRB2 Arg16Gly polymorphism on treatment response.
- To assess asthma control and exacerbation rates based on genetic profiling.
Main Methods:
- Individual participant data meta-analysis of two randomized controlled trials (PUFFIN and PACT).
- Inclusion of children (6-18 years) with uncontrolled asthma on ICS requiring treatment step-up.
- Randomization to genotype-guided treatment (LABA for Gly16/Gly16; double ICS or montelukast for Arg16/Arg16 or Arg16/Gly16) or control.
Main Results:
- No significant difference in asthma control between groups among 193 children.
- Genotype-guided treatment led to significantly lower asthma exacerbation rates (p=0.04).
- The A allele (Arg16) was present in 59% of participants.
Conclusions:
- Genotype-guided step-up asthma treatment may reduce exacerbation rates in children.
- This personalized approach could enhance asthma care strategies.
- Further research may validate genetic profiling for optimizing pediatric asthma management.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
236
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
236
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:29Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
01:20Asthma: Pathogenesis and Management
348
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
348
01:26Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
232
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
232